Technical Analysis for FNCH - Finch Therapeutics Group, Inc.

Grade Last Price % Change Price Change
C 13.29 -1.48% -0.20
FNCH closed down 1.48 percent on Tuesday, July 27, 2021, on 31 percent of normal volume.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Down Down
Historical FNCH trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Calm After Storm Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Outside Day Range Expansion 0.00%
MACD Bearish Centerline Cross Bearish -1.48%
Calm After Storm Range Contraction -1.48%
Narrow Range Bar Range Contraction -1.48%
NR7 Range Contraction -1.48%
Inside Day Range Contraction -1.48%
Calm After Storm Range Contraction -1.34%
Older End-of-Day Signals for FNCH ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Outside Day about 13 hours ago
Fell Below Previous Day's Low about 13 hours ago
Down 1% about 13 hours ago
Rose Above Previous Day's High about 14 hours ago
Up 1% about 14 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Finch Therapeutics Group, Inc. Description

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that has completed Phase II clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and FIN-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and crohn's disease. The company has collaboration and license agreements with Millennium Pharmaceuticals, Inc.; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Clinical Medicine Autoimmune Diseases Infection Specialty Drugs Colitis Ulcerative Colitis Abdominal Pain Diarrhea Crohn's Disease Autism Spectrum Disorder Chronic Hepatitis B Virus Clostridioides Difficile University Of Minnesota

Is FNCH a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 22.5
52 Week Low 11.56
Average Volume 85,229
200-Day Moving Average 0.00
50-Day Moving Average 14.51
20-Day Moving Average 14.78
10-Day Moving Average 14.98
Average True Range 1.21
ADX 24.77
+DI 14.74
-DI 26.60
Chandelier Exit (Long, 3 ATRs) 13.38
Chandelier Exit (Short, 3 ATRs) 15.79
Upper Bollinger Bands 16.88
Lower Bollinger Band 12.69
Percent B (%b) 0.14
BandWidth 28.33
MACD Line -0.18
MACD Signal Line 0.11
MACD Histogram -0.2921
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 14.01
Resistance 3 (R3) 14.08 13.90 13.89
Resistance 2 (R2) 13.90 13.72 13.87 13.85
Resistance 1 (R1) 13.60 13.61 13.51 13.53 13.81
Pivot Point 13.42 13.42 13.38 13.39 13.42
Support 1 (S1) 13.12 13.24 13.03 13.05 12.77
Support 2 (S2) 12.94 13.13 12.91 12.73
Support 3 (S3) 12.64 12.94 12.69
Support 4 (S4) 12.57